Mechanoporation-based Intracellular Delivery of Functional Molecules for Primary Immune Cell Engineering 2252000

Abstract Introduction Current intracellular delivery methods face significant limitations, including a restricted range of compatible molecules and cell types, as well as unintended alterations to cell biology. CellPore™ Transfection System addresses these limitations by using mechanoporation technology to efficiently deliver mRNAs, CRISPR-Cas9 ribonucleoproteins (RNPs), siRNAs, proteins and other molecules to the cytosol. Methods Recent platform enhancements, including the introduction of new cartridge sizes, have expanded compatibility to a wider range of cell types. These include unactivated and activated primary immune cells (e.g. T, NK, B and myeloid cells), hematopoietic stem and progenitor cells and pluripotent stem cells, which traditionally have been challenging to reliably engineer via conventional methods. Results In the context of immunology applications, we demonstrate efficient RNP-mediated knockout of surface MHC-I (74%) or TCRÉ’β (94%) in human T cells, and TIGIT (84%), CD16 (66%), NKG2A (81%) or NKp46 (87%) in human NK cells, with minimal impact to cell viability and function. We also demonstrate delivery of reporter mRNA and siRNA to monocytes and monocyte-derived dendritic cells for enabling transient gene expression and RNAi-mediated gene knockdown. Conclusion The CellPore™ system offers a gentle and efficient method to engineer a variety of cell types with a wide range of molecules. The simple and versatile workflow makes this a valuable tool for enabling new areas of research. Funding Source n/a Topic Categories Technological Innovations in Immunology (TECH)

Authors

Institutions

Publication Details

Journal
The Journal of Immunology
Published
2026-07-28
DOI
https://doi.org/10.1093/jimmun/vkag141.130
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mechanoporation-based Intracellular Delivery of Functional Molecules for Primary Immune Cell Engineering 2252000

Éric Ouellet, Nooshin Tabatabaei-Zavareh, Ulrike Lambertz, Elinor Binson et al.
The Journal of Immunology
CAR-T cell therapy research
article

Mechanoporation-based Intracellular Delivery of Functional Molecules for Primary Immune Cell Engineering 2252000

Éric Ouellet, Nooshin Tabatabaei-Zavareh, Ulrike Lambertz, Elinor Binson, Phillip Chau, Tina Liao, Gil Paik, Allen Eaves, Sharon Louis, Andy Kokaji, Quan Nguyen
article en

Abstract

Abstract Introduction Current intracellular delivery methods face significant limitations, including a restricted range of compatible molecules and cell types, as well as unintended alterations to cell biology. CellPore™ Transfection System addresses these limitations by using mechanoporation technology to efficiently deliver mRNAs, CRISPR-Cas9 ribonucleoproteins (RNPs), siRNAs, proteins and other molecules to the cytosol. Methods Recent platform enhancements, including the introduction of new cartridge sizes, have expanded compatibility to a wider range of cell types. These include unactivated and activated primary immune cells (e.g. T, NK, B and myeloid cells), hematopoietic stem and progenitor cells and pluripotent stem cells, which traditionally have been challenging to reliably engineer via conventional methods. Results In the context of immunology applications, we demonstrate efficient RNP-mediated knockout of surface MHC-I (74%) or TCRÉ’β (94%) in human T cells, and TIGIT (84%), CD16 (66%), NKG2A (81%) or NKp46 (87%) in human NK cells, with minimal impact to cell viability and function. We also demonstrate delivery of reporter mRNA and siRNA to monocytes and monocyte-derived dendritic cells for enabling transient gene expression and RNAi-mediated gene knockdown. Conclusion The CellPore™ system offers a gentle and efficient method to engineer a variety of cell types with a wide range of molecules. The simple and versatile workflow makes this a valuable tool for enabling new areas of research. Funding Source n/a Topic Categories Technological Innovations in Immunology (TECH)

The Journal of ImmunologyVol. 215(Supplement_1)
Stemcell Technologies (CA), Terry Fox Research Institute (CA)
Industry, innovation and infrastructure
Openalex Percentile: Top 11%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.